Hostile personality characteristics, dysthymic states and neurotic symptoms in urticaria, psoriasis and alopecia.

Three experimental groups of patients with urticaria, psoriasis and alopecia were compared for hostile personality characteristics, states of anxiety and depression, neurotic syndromes and stress with a control group of patients with other skin diseases. The patients from each experimental group were found to be less dominant, more intropunitive, more extrapunitive and more neurotic than the control group. The following neurotic syndromes differentiated the experimental groups: non-specific anxiety states in urticaria patients; neurotic depression in the patients with alopecia, and a variety of neurotic syndromes in the psoriasis patients. All experimental groups scored significantly higher than the controls in stress experienced during the year preceding the onset or the exacerbation of the illness.

Psychological characteristics of hypertensive and ulcer patients.

Hypertensive and duodenal ulcer patients were compared with physically ill patients at admission and discharge on personality traits and states of anxiety and depression. Both the hypertensive and ulcer patients were less dominant and more anxious than the control group at admission, while depression differentiated only the hypertensive group. The hypertensive patients were more depressed and more anxious than the ulcer patients at admission. At discharge, both experimental groups remained less dominant than the control group and the hypertensives remained more anxious and more depressed than the ulcer and control groups. Low dominance was correlated with high blood pressure and high extrapunitiveness was correlated with E.C.G. abnormality in the hypertensive patients. The results are discussed with respect to the role of aggression and low dominance in these 'psychosomatic' disorders.

Mobilization of refractory chronic schizophrenics with haloperidol.

Adequate high doses of haloperidol have been administered to 24 chronic, refractory to standard antipsychotic treatment, schizophrenics (16 male, 8 female, mean age 32.9 years) to investigate the possibility of mobilizing and releasing these patients from the hospital. Treatment was started with 20 mg haloperidol and optimal doses were determined for each patient. The median daily optimal dose at the end of the trial was 100mg. All patients were followed up for 16 weeks. Evaluating criteria were the BPRS, the Discharge Readiness Questionnaire, a side-effect rating scale, a CGI scale and the number of patients able to leave the hospital. 3 patients were evaluated as able to leave the hospital. 87.4% of the patients were subjectively evaluated as improved. High doses of haloperidol did not correlate with a higher incidence of unwanted effects. On the contrary antiparkinson treatment was discontinued or decreased in 14 patients. It is concluded that nonresponsive chronic schizophrenics can profit from adequate high doses of haloperidol.